Non-alcoholic steatohepatitis (NASH) is strongly associated with overnutrition, insulin resistance, and predisposition to type 2 diabetes. To critically analyze the translational significance of currently used animal models of NASH, we reviewed articles published during the last 3 years that studied NASH pathogenesis using mouse models. Among 146 articles, 34 (23%) used models in which overnutrition was reported, and 36 (25%) demonstrated insulin resistance, with or without glucose intolerance. Half the articles contained no information on whether mice exhibited overnutrition or insulin resistance. While 75 papers (52%) reported > 2-fold increase of serum/plasma alanine aminotransferase (ALT) compared with controls, ALT levels were near normal or not reported in 48%. Liver pathology was assessed by a pathologist with an interest in liver pathology in 53% of articles published in gastroenterology/hepatology journals, versus 43-44% in other journals. While there appears to be a trend to use models that are potentially relevant to the pathogenesis of human NASH, journals currently publish data on mouse models in which overnutrition and insulin resistance do not occur, without ALT increase or appropriate analysis of NASH pathology. We recommend that investigators, reviewers, and journal editors carefully consider the validity of NASH models in current use and that moves are made to reach a consensus on what the minimal criteria should be.
Introduction
Non-alcoholic fatty liver disease (NAFLD) affects one-third of the world's population. 1, 2 It results from oversupply of energy in relation to bodily needs, usually referred to as overnutrition, especially in those with a genetic predisposition to or established type 2 diabetes. 3 Obesity may or may not be present, but development of NAFLD is associated with visceral obesity, insulin resistance, hyperglycemia, atherogenic dyslipidemia, hypoadiponectemia, and arterial hypertension. 4, 5 NAFLD encompasses a spectrum of pathological severity ranging from steatosis only (SO) through non-alcoholic steatohepatitis (NASH) in which fibrosis may be present. The disease outcomes include cirrhosis and hepatocellular carcinoma. 6 Non-alcoholic steatohepatitis is the pathological form of NAFLD in which steatosis is complicated by lobular mixed inflammation (pattern seen in adults; portal inflammation is typically seen in children), hepatocellular injury, and cell death, often with inflammation-driven fibrosis. 7, 8 The processes additional to steatosis, such as substantial inflammation and hepatocyte injury and cell death, are likely pathological responses to "liver lipotoxicity," triggered by hepatic accumulation of toxic lipids and lipid metabolites in addition to triglycerides. [9] [10] [11] [12] SO is attributable to accumulation of triglycerides alone.
Until the last decade, NASH pathogenesis was conceptualized by a "two-hit" hypothesis. 13 Accordingly, the first hit was considered to reflect excessive hepatic lipid partitioning, whereas the second hit induces a pro-injurious and pro-inflammatory response in the liver as the result of unrelated processes, such as oxidative stress and cytokines driven, for example, by gut microbiota.
14 Today, researchers in the field consider the two-hit hypothesis insufficient to describe the multistep pathogenesis of NASH. 15 The newer concept is that metabolic factors lead directly to NASH, and this is supported by the stronger association of NASH than SO with prediabetes and metabolic syndrome. By this concept, insulin resistance and resultant hyperinsulinemia drive the hepatic accumulation of lipotoxic lipids, such as free cholesterol, saturated free fatty acids, diacyglycerol, and lysophosphatidylcholine. [15] [16] [17] [18] [19] These more reactive lipid molecules can injure hepatocytes, with activation of innate immunity to initiate an inflammatory response.
For two decades, investigators have addressed questions about NASH pathogenesis using animal models, and increasingly, these are being used to test putative therapeutic molecules. 20, 21 Rodent (especially mouse) models have been most used. There has been excellent research on larger animals, such as miniature pigs 22 and opossums, 23 but this will not be considered further here. Earlier research used animal models showing SO because the focus was on interventions that could convert SO to steatohepatitis by the two-hit hypothesis. In rodents, production of SO occurs with a high carbohydrate or a high-fat diet (HFD), as well as with several genetic eating defects, such as ob/ob or db/db mice or fa/fa rats. 24 In 1996 to 2000, work from the Storr Liver Unit in Sydney, Australia, developed a rodent model of steatohepatitis (not caused by alcohol) 25 that was caused by a methionine-deficient and choline-deficient (MCD) diet.
In 2008, Larter and Yeh reviewed the metabolic features and histopathology that animal models should exhibit to reflect the human context and liver pathology of NASH. 26 Since then, an increasing number of animal models has been used in preclinical NASH research, and these models have been discussed in several reviews. 24, [27] [28] [29] [30] [31] [32] [33] However, while multiple etiological factors can cause steatohepatitis pathology, the relevance of some of these models to NASH as a clinical entity is questionable (Table 1) , and some fail to demonstrate the defining hallmarks of liver pathology.
The recent determination of biomedical journal editors to publish results of animal research only when studies conform to agreed international standards (Animal Research: Reporting of In Vivo Experiments [ARRIVE] ) is an important advance. 34 ARRIVE recommends reporting details of animals used, such as strain/ genetic fidelity, use of littermates, specifics of diet/nutrients, and other elements of humane and healthy animal husbandry. Beyond this, the basic precepts for experimental use of animals in research demand attention be given to their minimalization and effective use: replacement (by other technologies), reduction (of mouse numbers), and refinement (precision of use for stated purpose); together, these are summarized as "the three Rs". Anecdotally, we frequently raise concerns about model relevance when acting as journal reviewers. It is therefore timely this issue is raised and discussed in an informed manner in the field of hepatology. To initiate this discussion, we reviewed all studies over the last 3 years that employed mouse models claimed to represent NASH. We sought data about how often these models met what we regard as key preconditions, such as overnutrition, insulin resistance, glucose intolerance, and disease operation-such as liver injury, and a specialist pathologist's assessment of liver pathology. 
Methods
Search strategy. We performed a systematic literature search of all studies that report on NASH mouse models, using the criteria shown in Figure 1 . Electronic databases (MEDLINE and SCOPUS) were interrogated for original research articles published in English. Articles were selected if they contained the keywords "steatohepatitis, NASH, NAFLD, mouse, mice, model" in the title, abstract, and/or keywords. The operators "AND" and "OR" were used in the search algorithm to ensure that article abstracts included at least three of these keywords.
Study selection and eligibility criteria. From January 1, 2015 to September 1, 2017, 270 articles were found. Secondary criteria were then applied ( Fig. 1 ) to include only journals with impact factor ≥ 3 and to exclude studies uniquely reporting lipodystrophy-associated disorders or hepatocellular carcinoma. After eliminating articles that did not meet the secondary criteria, 146 (unique) full-text articles were downloaded. Two authors (F. H. and G. C. F.) confirmed that each study provided sufficient information to be included in the detailed analysis (Table S1 ). To establish whether the number of research articles in this field is changing, we applied the same primary search criteria to articles published in 2012-2014 but without further detailed analysis.
Outcome measures
Journals. Journals were grouped as "gastroenterology/ hepatology" (e.g. Hepatology, Journal of Hepatology, and Gastroenterology), "metabolism" (e.g. Metabolism, The Journal of Lipid Research, and Obesity), "pharmacology" (e.g. Journal of Pharmacology and Experimental Therapeutics and Acta Pharmacologica Sinica), and "other" (e.g. The Journal of Clinical Investigation, Clinical Science, and Oncotarget).
Classification of model type. In this review, models with a genetic manipulation were called "genetic models" regardless of the diet(s) employed, whereas models that have no genetic defect or manipulation were considered as "dietary models." Genetic mouse models of NASH included defects of (i) appetite regulation and (ii) metabolic regulation. In the first group, mice carry a defect in hypothalamic regulation of appetite that results in increased food intake and early-onset obesity akin to monozygotic childhood obesity in humans. Examples include melanocortin 4 receptor knockout (Mc4r À/À ) 35 and Alms1-mutant (foz /foz) [36] [37] [38] mice. In such models, hyperinsulinemia and diabetes occur because of metabolic dysregulation and not direct effect of genetic manipulation. With a balanced rodent (chow) diet, animals develop SO, whereas feeding atherogenic diet causes NASH. With metabolic defects, leptin-deficient ob/ob (Lep ob ) and leptin receptor-deficient db/db (Lepr db ) mice have impaired leptin responses and develop early-onset obesity, hyperglycemia, hyperinsulinemia, and NAFLD, especially when fed high-calorie diets, 39 although hepatic injury and inflammatory infiltration remain mild. Other genetic NASH models include phosphatase and tensin homolog-deficient and low-density lipoprotein receptor knockout (Ldlr À/À ) mice. In these models, metabolic regulation differs from that of human NASH, but development of steatohepatitis could provide insights into inflammatory recruitment and liver outcomes. There are several diet-induced mouse models of steatohepatitis. Diet-induced obesity (obesogenic) is produced by provision of Figure 1 Search processes for inclusion of relevant studies. NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
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excess calorie intake without measures to increase physical activity correspondingly. Because studies of hepatic lipid fractions in human NASH show excessive accumulation of free cholesterol, [40] [41] [42] researchers have also used diets high in both fat and cholesterol; these have been variously referred to as atherogenic, Western, or fast food diet. Nutrient-deficient models are based on the absence of choline and methionine, which causes dysregulation of β-oxidation and lipoprotein production to increase hepatic lipid partitioning 43, 44 ; these diets may include high sucrose and/or fat content to mitigate reductions in body weight. Although we do not favor use of drug or toxin toxicity to develop steatohepatitis, hepatotoxic models have been included in the dietary group because most are supported by high-calorie diets. In the STAM mouse model, streptozotocin (STZ) deletes pancreatic β cells to impair insulin production; STZ-injected HFD-fed mice develop liver damage and fibrosis. However, STZ also has direct effects on hepatocytes. 45 Carbon tetrachloride (CCl 4 ) has also been used to generate fatty liver with fibrosis in mice; some authors have described the pathology as NASH.
Metabolic factors. Metabolic factors recognized to be "established associations to NASH development" by the three largest regional liver societies are listed in Table 2. 46-48 We focused on overnutrition, insulin resistance, and impaired glucose metabolism in this review.
Liver pathology. Because NASH (vs SO) is associated with liver injury and frequent increases in serum alanine aminotransferase (ALT), we surveyed serum/plasma levels of ALT, noted as increased > 2-fold, increased ≤ 2-fold, data not presented or not mentioned, or uninterpretable data (when there was no appropriate control for comparison). The distinction of NASH from SO is clinically important because NASH (with hepatocyte injury, i.e. ballooning) is more often associated with fibrosis than is SO. While expert pathologists have developed different histological scoring systems, the NAFLD activity score (NAS) developed by Kleiner et al. of the Pathology Subcommittee of the NIH NASH Clinical Research Network has been most used in clinical trials. 49 NAS was not devised for semi-quantification of NAFLD characteristics in mouse models but has the advantage of considering all three key criteria required for definition of NASH: steatosis, hepatocyte injury (as ballooning), and lobular inflammation ( Table 2 ). Fibrosis can be scored separately by the system devised by Elizabeth Brunt, as modified by the committee earlier. 7 Finally, Brunt et al. 7 and Kleiner et al. 49 have emphasized the difference between the NAS, in which values ≥ 5 (of max 8 points) are usually associated with NASH, versus the diagnosis of NASH that can only be made after global assessment of the liver pathology by an experienced liver pathologist. We scrutinized all reports for methods of assessing liver pathology, whether NAS (or a similar scoring system) was used and whether a pathologist was involved in global assessment of liver pathology for possible NASH.
Results
Publication characteristics. Details of the 146 studies reviewed are in Table S1 : 53 (36%) were published in gastroenterology/hepatology journals, 30 (21%) in metabolism, 9 (6%) pharmacology, and 54 (37%) other journal categories. By experimental design, 108 studies (74%) reported data on dietary models, while 38 studies (26%) incorporated a genetic model. The use of genetic models was the highest among studies published in gastroenterology/hepatology journals (genetic 34% vs 66% dietary) compared with 30% in metabolism, 20% other, and none among articles published in pharmacology journals. A brief survey of earlier years (using only the primary descriptors) indicated an apparent recent increase (~3-fold) in the number of articles employing NASH mouse models since 2012 (Fig. S1 ). Human studies also mandate certain exclusion criteria for NASH definition, such as high alcohol intake, viral hepatitis, drug-induced liver disease, autoimmune hepatitis. AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
Among 146 articles, only 34 (23%) studies used models in which overnutrition was reported (Fig. 2) , and 36 (25%) studies demonstrated insulin resistance, with or without glucose intolerance (Fig. 2) . The largest proportion of articles contained no information on whether the models exhibited overnutrition, insulin sensitivity, or metabolic complications that are associated with human NASH. Likewise, only 75 papers (52%) reported > 2-fold increase of serum/plasma ALT levels compared with controls (Fig. 2) .
Characteristics of genetic models. The most commonly used was ob/ob mice (11 articles, 29% of genetic model articles) followed by db/db (4 articles, 11%) and foz /foz (6 articles, 16%). Others included phosphatase and tensin homolog-KO and Ldlr À/À mice. Among genetic model studies, 12 (32%) reported body weight > 40 g, 8 (21%) exhibited body weight ≤ 40 g, and nearly half (47%) failed to report body weight data (Fig. 3) . Some studies did mention weight gain after the start of the diet but failed to mention final body weight. Insulin resistance alone or with glucose intolerance and diabetes was reported in 10 (26%) genetic model studies (Fig. 3) . Again, 11 (29%) showed no evidence of insulin resistance/diabetes, and nearly half (45%) did not provide results about insulin sensitivity in the model used. Nineteen studies (50%) reported elevated serum/plasma ALT levels > 2-times higher than no NASH controls; in 6 studies (16%), ALT was not increased or the increase failed to exceed twofold compared with controls. There was no information about ALT in 10 studies (26%) and no relevant control (e.g. mutant vs wild type) in 3 (8%) studies (Fig. 3) .
Characteristics of dietary models. A wide range of different dietary regimes was used. The most common was the MCD diet (42 articles, 39%), followed by the choline-deficient amino acid-defined diet (CDAA) (8 articles, 7%), high-fat-only diet (18 articles, 17%), and high fat with cholesterol diet (16 articles, 15%). Several other studies (n = 22) incorporated an HFD with cholesterol and/or high carbohydrate, variously referring to the diet as "Western," "fast food," or "atherogenic." The cholesterol content ranged from 0.02% to 2% by weight, or remained undefined. Only 22 (20%) of dietary studies reported body weight > 40 g, and in the majority of dietary models (39%), mice did not gain excessive body weight (Fig. 4) . Further, 44 studies (41%) failed to , no information), insulin resistance and diabetes, and blood alanine transaminase (ALT) results ( , increase > 2×; , increase ≤ 2×;
, no information; , no control) for all (146) articles reviewed using a non-alcoholic steatohepatitis (NASH) mouse model ( , genetic model;
, dietary model). [Color figure can be viewed at wileyonlinelibrary.com] Figure 3 Reported body weight ( , yes; , no; , no information), insulin resistance and diabetes, and blood alanine transaminase (ALT) results ( , increase > 2×; , increase ≤ 2×; , no information; , no control) in reviewed articles using genetic models of non-alcoholic steatohepatitis (NASH). [Color figure can be viewed at wileyonlinelibrary.com] Systematic review of mouse NASH modelsreport final body weight after the dietary regime. Only 26 studies (24%) showed evidence of insulin resistance and/or diabetes in the model used, 40 studies (37%) found no such evidence, and 42 studies (39%) contained no relevant information (Fig. 4) . The number of studies employing a dietary model in which blood ALT levels increased > 2-fold control values was 56 (53%), whereas nine studies (8%) showed normal or very mild (≤ 2-fold) ALT increase. Thirty-four studies (32%) contained no information about blood ALT, and seven (7%) reported ALT without reference to a control group (e.g. HFD fed vs chow fed), which we deemed uninterpretable data (Fig. 4) .
Analyses of liver histopathology. We analyzed the 146 articles as to whether they contained a pathologist's assessment of NAFLD pathology. Among studies published in gastroenterology/ hepatology journals, 53% provided a pathologist's analysis of NASH. This proportion was less (43-44%) in metabolism, pharmacology, and other journals. In terms of model type, studies with a diet-induced NASH model were more likely to contain an appropriate analysis of liver pathology than those employing a genetic model (51% vs 45%). An additional finding was that some authors had "invented" their own version of NAS, misnaming it as the "NASH activity score," or in some instances, eliminating the hepatocellular injury component conferred by scoring hepatocyte ballooning.
Discussion
The need for a detailed understanding of NASH pathogenesis so as to design effective pharmacological intervention is among the highest priorities in contemporary hepatology. The nexus between overnutrition, usually that causing overweight or obesity, and NASH is supported by a wealth of clinical studies and underscored mechanistically by the complete reversal of NASH pathology that occurs with 10% weight loss. 50, 51 For this reason, the 2017 AsiaPacific Guidelines on NAFLD, broadly in accord with EASL and AASLD Guidelines, define NAFLD and its complication of NASH as a disorder that can reasonably be attributed to overnutrition and its complications, such as weight gain, central obesity, development of insulin resistance with glucose intolerance, and metabolic syndrome. 46 Lipotoxicity is now a favored concept for NASH pathogenesis. However, there is an outstanding need to elucidate details about what appears to be a network of maladaptive responses in the liver and whole body that lead to the liver pathology of NASH. Because it is difficult to study dynamic tissue changes in the human liver, investigators have developed and used animal models, especially mouse models for this purpose. Animal models also provide an essential platform for early studies of drug intervention against NASH.
The number of articles reporting studies into the pathogenesis or treatment of NASH using mouse models has increased from~40 per year in 2012 to currently over 100 per year (139 articles in 2017; Fig. S1 ). Twenty years ago, the central tenant about NASH pathogenesis was that obesity and metabolic factors (e.g. diabetes) are simply the setting for NASH-a separate pro-injurious and pro-inflammatory "hit" was required to transform steatosis to steatohepatitis. The more integrated idea of lipotoxicity resulting from "unhealthy obesity" (overnutrition complicated by insulin resistance) requires different animal models for study, ones that reflect a direct metabolic causation of NASH. Our anecdotal experience as reviewers of articles submitted to biomedical journals suggested that investigators and journals have not yet established standards of what should be the minimal requirements for a relevant animal model of NASH, such as those listed in Table 3 . As articulated by Larter and Yeh, 26 we consider that models that reflect both the metabolic context and similar liver pathology of human NASH would seem most relevant. To establish a decade later how widespread is the use of such models, we conducted a systematic review of articles about the pathogenesis or drug treatment of NASH, noting whether the animals used became overnourished (body weight > 40 g) and developed Figure 4 Reported body weight ( , yes; , no; , no information), insulin resistance and diabetes, and blood alanine transaminase (ALT) results ( , increase > 2×; , increase ≤ 2×; , no information; , no control) in reviewed articles using dietary models of non-alcoholic steatohepatitis (NASH). [Color figure can be viewed at wileyonlinelibrary.com] insulin resistance and/or glucose intolerance/diabetes and recording how liver pathology was assessed. While we are unable to make a value judgment about the quality of articles or their likely contribution to knowledge, we were surprised that less than one quarter of them reported on animal body weight attaining a value that reflects mouse obesity; about the same proportion reported body weights in the normal range, and fully one-half failed to report any data on body weight. Some mouse model studies mentioned weight gain after commencement of dietary regimens but failed to mention the final body weight. There is current debate about the proportion of patients with NASH who are not obese, up to 25% in some Asian series, but most of these cases have exhibited weight gain, they often show central adiposity, commonly give a family history of type 2 diabetes, and, if tested, they virtually always have insulin resistance. 52 We therefore propose that the use of models where at least half of mice are not overweight, up to 75% if the absence of data in 50% of the papers is because there was no weight gain, is a substantive difficulty.
The metabolic complications of overnutrition pertinent to NASH pathogenesis center around insulin resistance. This may be evident with fasting hyperinsulinemia and calculated (by also considering fasting blood glucose) using the homeostatic model assessment for insulin resistance score, or by a physiological challenge such as an intraperitoneal glucose tolerance test, which is simpler to perform on mice than the technically more demanding "gold standard" of an insulin and glucose infusion clamp test. One quarter (10, 26%) of studies employing genetic models (usually with a dietary regimen) demonstrated insulin resistance alone or with glucose intolerance and diabetes, 11 (29%) found no insulin resistance, and 18 (45%) provided no relevant information. Rather similarly, 26 (24%) of studies in purely dietary models reported insulin resistance and/or diabetes, 39 (36%) found no evidence of insulin resistance, and 42 (39%) failed to provide the relevant information. As for overnutrition, if somewhere between 26% and 74% (worst case scenario if failure to provide pertinent information always reflected insulin resistance was not present) of articles are about fatty liver without insulin resistance, the literature on NASH pathogenesis using mouse models could be seriously flawed as at least 98% of humans with NASH have insulin resistance. 53 By definition, NASH involves liver injury and a specific pattern of liver pathology to define its presence. Despite this, we found only 50% of studies using genetic models documented blood ALT increase > 2-fold versus control values, 53% using a dietary model, while up to 16% of genetic model and 8% of dietary model research reported normal ALT values, and 13-25% failed to mention any ALT (or AST) data. In addition, 7% of studies failed to use an appropriate control (e.g. wild-type mice in genetic studies and chow-fed mice in dietary studies). According to recommendations for the interpretation of liver pathology required for the diagnosis of human NASH, attempts to document the phenotype and severity of fatty liver pathology in mouse model research were also deficient, particularly in nonspecialist gastroenterology/ hepatology journals. Thus, among all 146 articles surveyed, only about half (53%) of those published in gastroenterology/ hepatology journals used an experienced liver pathologist to interpret liver pathology, versus less than half (43-44%) in other journals.
Given the dearth of consensus about what might or might not be appropriate animal models to study NASH pathogenesis or test putative therapeutic molecules, it is premature to call for a moratorium on specific mouse models that otherwise comply with international and local institutional standards for ethical experimentation (ARRIVE). That stated, we are concerned with the number of articles that still use the MCD model, which we introduced to this field in 1996, 25 and refined for mice in 2000. 43 Between 2015 and 2017, the MCD model was used by authors of 42 articles, 39% of all dietary models. The time of dietary exposure (sometimes not stated) varied from 2 to 20 weeks, most typically 4 weeks, whereas we have noted it takes~3 weeks for steatohepatitis pathology to evolve and at least 5 weeks for histologically apparent fibrosis. 54 Authors rarely if ever stated the reason for such short duration of their studies, but we note that after 3-4 weeks, MCD-fed mice lose~20% of their starting body weight and by 8 weeks have generally lost 40% of body weight (the smallest mouse we noted in the reviewed studies weighed 12 g). Further, mice fed with MCD diet are unusually insulin sensitive rather than the contrary, while the development of steatohepatitis pathology makes the model of interest to NASH, livers do not show hepatocyte ballooning typical of the human condition. 30 The CDAA model avoids extreme weight loss in a choline-deficient model that is less restricted in essential amino acids, but authors have yet to report on physiological studies of insulin sensitivity and rarely provide metabolic indices such as fasting serum insulin, blood glucose, and serum lipids.
Other dietary models can produce overnutrition, insulin resistance, and NASH pathology as documented by NAS ≥ 5 and/or experienced liver pathologist assessment. Those that contain both high fat and high cholesterol (for a rodent) seem most likely to provide all these dimensions, although many such diets use inhouse dietary formulation without documenting the source and nutrient content of ingredients (e.g. lard and milk fat). Diets better described as high fat or high carbohydrate (alone) rarely produce liver injury with ALT elevation or convincing liver pathology showing steatohepatitis. Finally, we encountered articles that used a toxic regimen, usually repeated CCl 4 administration, to produce fatty liver pathology that some authors claimed represented NASH. While forms of drug-induced liver injury such as that due to tamoxifen, amiodarone, and nifedipine can cause steatohepatitis pathology, this is better regarded as a different condition (drug-induced steatohepatitis), not NASH. 55 
Conclusions
This systematic review found that a large range of mouse models is currently being used to study NASH pathogenesis and treatment. Some are purely dietary, others genetic, or genetic manipulations with or without exposure to one or more diets. We are not convinced that all such models provide data of sound validity for a better understanding of NASH and its treatment, and there is need for international consensus in this area. In particular, we wonder whether all models should show weight gain (or indicate reasons why this is not relevant to the study objective), liver injury (serum enzymes and/or ballooning and/or measures of cell death), and substantial liver inflammation. Finally, we recommend that a pathologist with experience in human fatty liver disease be integrally involved with at least the initial description of a new animal Systematic review of mouse NASH modelsmodel of NASH. Observed from an ethical viewpoint, many details in animal experimentation (as in "ARRIVE") are now regarded as a prerequisite for publication of articles in major biomedical journals. 34 In our view, such thinking should extend to whether it is logistically or ethically justified to publish articles in which the authors purport to be studying NASH when insufficient evidence has been provided to support such a claim. Our purpose in pointing out this concern is to improve the quality of biomedical research into NASH pathogenesis and treatment.
